Organovo Halts Liver Tissue R&D, Plans Restructuring to Cut Costs
Xconomy
AUGUST 7, 2019
The San Diego-based biotech has been working since 2007 to use a method known as bio-printing to come up with such a product, which Organovo (NASDAQ: ONVO ) was developing for patients with end-stage liver disease and a group of rare diseases that also necessitate organ transplantation.
Let's personalize your content